Objectives: The aim of this study is to evaluate clinically the local hemostatic effect of Ethyl-cyanoacrylate(Epiglu) in anticoagulant(warfarin) treated patients undergoing surgical removal of class I mesioanglar Impacted mandibular third molar without change in their anticoagulant level and evaluate the possible post operative complications. Materials and Methods: 20 patients, under oral anticoagulant therapy, divided into two groups In which 10 patients, Hemostasis and primary closure were obtained with use of gelatin sponge and multiple interrupted resorbable suture vicryl (control group) .In the other group (study group)10 patients, Hemostasis and primary closure were obtained with use of gelatin sponge and minimal interrupted resorbable suture and( Epiglu)application.. Results: At day of surgery, control group showed statistically significantly higher prevalence of spontaneous bleeding than study group ( P ≤ 0.25)(Significant at P ≤ 0.05)At first day post-operatively, there was no statistically significant difference between the two groups .At second day, third day and 1 week post-operatively, both groups didn’t show any spontaneous bleeding. At first day post-operatively, there was no statistically significant difference in induced bleeding between the two groups. At second day, third day and 1 week post-operatively, both groups didn’t show any induced bleeding. There was no statistically significant difference between the two groups in the trismus at the first and third day post operatively. At first day post-operatively, Study group showed statistically significantly higher mean edema measurement than control group.At third day post-operatively There was no statistically significant difference between the two groups in edeama measurement. Conclusion: It was concluded from this study, that The patients using Warfarin as an anticoagulant could do their surgical dental extraction safely without interruption of the anticoagulant with the use of Ethyl-cyanoacrylate adhesive glue and suturing of the wound providing that their INR range from (1.5 to3) , Patients should not have a history of liver disease and should not be taking any other drug affecting liver function and postoperative hemostasis.